HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Dietmar W Siemann Selected Research

combretastatin A-4 (combretastatin A4)

5/2007Characterizing the tumor response to treatment with combretastatin A4 phosphate.
6/2006Current development status of small-molecule vascular disrupting agents.
6/2004Vascular-targeting therapies for treatment of malignant disease.
5/2002Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy.
1/2002Preclinical evaluations of therapies combining the vascular targeting agent combretastatin A-4 disodium phosphate and conventional anticancer therapies in the treatment of Kaposi's sarcoma.
1/2002Activity of the vascular targeting agent combretastatin A-4 disodium phosphate in a xenograft model of AIDS-associated Kaposi's sarcoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Dietmar W Siemann Research Topics

Disease

56Neoplasms (Cancer)
11/2015 - 01/2002
11Necrosis
03/2014 - 01/2002
8Neoplasm Metastasis (Metastasis)
11/2015 - 07/2005
7Sarcoma (Soft Tissue Sarcoma)
07/2007 - 05/2002
6Renal Cell Carcinoma (Grawitz Tumor)
06/2014 - 11/2004
6Prostatic Neoplasms (Prostate Cancer)
03/2012 - 05/2010
3Breast Neoplasms (Breast Cancer)
11/2015 - 01/2013
3Anoxia (Hypoxia)
04/2014 - 09/2011
3Osteosarcoma (Osteogenic Sarcoma)
03/2014 - 01/2009
3Colorectal Neoplasms (Colorectal Cancer)
07/2006 - 06/2002
3Kaposi Sarcoma (Kaposi's Sarcoma)
11/2004 - 01/2002
3Ischemia
06/2004 - 05/2002
2Carcinoma (Carcinomatosis)
06/2009 - 11/2005
2Squamous Cell Carcinoma (Epidermoid Carcinoma)
06/2009 - 07/2005
2Acquired Immunodeficiency Syndrome (AIDS)
01/2002 - 01/2002
1Glioblastoma (Glioblastoma Multiforme)
04/2015
1Adenomatous Polyposis Coli (Familial Adenomatous Polyposis)
04/2013
1Pathologic Neovascularization
01/2013
1Leukemia
09/2010
1Myeloid Sarcoma (Chloroma)
09/2010
1Adenocarcinoma
03/2010
1Lung Neoplasms (Lung Cancer)
11/2009
1Infection
11/2006
1Vascular Tissue Neoplasms
04/2004

Drug/Important Bio-Agent (IBA)

13glucuronyl glucosamine glycan sulfate (Vessel)IBA
06/2014 - 11/2002
12Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
04/2015 - 01/2004
7Oxi 4503IBA
06/2014 - 07/2006
6combretastatin A-4 (combretastatin A4)IBA
05/2007 - 01/2002
6N-acetylcochinol-O-phosphateIBA
11/2005 - 05/2002
5N- (4- bromo- 2- fluorophenyl)- 6- methoxy- 7- ((1- methylpiperidin- 4- yl)methoxy)quinazolin- 4- amine (ZD6474)IBA
04/2015 - 11/2004
5OxygenIBA
01/2014 - 11/2002
5Phosphotransferases (Kinase)IBA
08/2012 - 06/2010
5Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
08/2012 - 07/2006
45,6-dimethylxanthenoneacetic acidIBA
11/2010 - 05/2002
4Waste Products (Waste Product)IBA
01/2009 - 01/2003
4Cisplatin (Platino)FDA LinkGeneric
11/2005 - 01/2002
3Cathepsin LIBA
11/2015 - 10/2013
3bevacizumabFDA Link
05/2013 - 07/2008
3N- (4- (2- amino- 3- chloropyridin- 4- yloxy)- 3- fluorophenyl)- 4- ethoxy- 1- (4- fluorophenyl)- 2- oxo- 1,2- dihydropyridine- 3- carboxamideIBA
03/2012 - 06/2010
3tyrosine receptor (receptor, tyrosine)IBA
02/2012 - 06/2010
2Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
04/2015 - 07/2006
24- ((4- Fluoro- 2- methyl- 1H- indol- 5- yl)oxy)- 6- methoxy- 7- (3- (pyrrolidin- 1- yl)propoxy)quinazoline (AZD2171)IBA
04/2015 - 03/2009
2sunitinib (Sutent)FDA Link
06/2014 - 01/2014
2Hemoglobins (Hemoglobin)IBA
06/2014 - 01/2014
2Angiogenesis InhibitorsIBA
01/2014 - 04/2004
2Cadherins (E-Cadherin)IBA
06/2013 - 05/2010
2Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA
01/2012 - 06/2010
2HOE 33342 (Hoechst 33342)IBA
07/2006 - 05/2002
2EndostatinsIBA
01/2003 - 06/2002
1Peptide Hydrolases (Proteases)IBA
11/2015
1matrigelIBA
11/2015
1Norepinephrine (Noradrenaline)FDA LinkGeneric
04/2014
1Gold Sodium Thiomalate (Sodium Aurothiomalate)IBA
03/2014
1Caspase 3 (Caspase-3)IBA
03/2014
1aldehyde dehydrogenase 1IBA
06/2013
1DNA (Deoxyribonucleic Acid)IBA
04/2013
1SmokeIBA
04/2013
1Adenosine Triphosphate (ATP)IBA
08/2012
1Angiopoietin-2IBA
05/2012
1dasatinib (BMS 354825)FDA Link
02/2012
1Eosine Yellowish-(YS) (Eosin)IBA
01/2012
1Hematoxylin (Haematoxylon)IBA
01/2012
1Conditioned Culture MediaIBA
01/2012
13- (5'- hydroxymethyl- 2'- furyl)- 1- benzylindazole (YC 1)IBA
10/2011
1combretastatinIBA
01/2011
1TubulinIBA
01/2011
1Messenger RNA (mRNA)IBA
05/2010
1Small Interfering RNA (siRNA)IBA
05/2010
1Transcription Factors (Transcription Factor)IBA
05/2010
1RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA
05/2010
1AgarIBA
05/2010
1Chemokine CXCL12IBA
11/2009
1Neutralizing AntibodiesIBA
11/2009
1Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA
03/2009
1PlasticsIBA
01/2009
1Dihydrotachysterol (AT 10)IBA
01/2009
1Proteins (Proteins, Gene)IBA
07/2007
1Angiogenesis Inducing Agents (Angiogenesis Factor)IBA
11/2006
1SiliconIBA
11/2006
1Monoclonal AntibodiesIBA
09/2006
1MN-029IBA
11/2005
1carbogenIBA
07/2005
1FluorineIBA
12/2004
1EtanidazoleIBA
12/2004
1Peptide Elongation Factor 1 (1, EF)IBA
11/2002
1Cyclophosphamide (Cytoxan)FDA LinkGeneric
05/2002
1Acetic Acid (Vinegar)FDA LinkGeneric
05/2002
1Vinblastine (Vinblastine Sulfate)FDA Link
01/2002

Therapy/Procedure

11Heterologous Transplantation (Xenotransplantation)
03/2014 - 01/2002
7Aftercare (After-Treatment)
06/2014 - 01/2002
6Radiotherapy
02/2011 - 05/2002
6Drug Therapy (Chemotherapy)
02/2011 - 01/2002
3Nutritional Support (Artificial Feeding)
09/2015 - 04/2004
2Therapeutics
06/2004 - 11/2002
2Intramuscular Injections
01/2003 - 06/2002
1Immunotherapy
09/2006
1Intraperitoneal Injections
11/2005
1Particle Accelerators
05/2002